LY333328对耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌和耐青霉素肺炎链球菌的体外活性。
In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
作者信息
Patel R, Rouse M S, Piper K E, Cockerill F R, Steckelberg J M
机构信息
Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA.
出版信息
Diagn Microbiol Infect Dis. 1998 Feb;30(2):89-92. doi: 10.1016/s0732-8893(97)00207-1.
We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 micrograms/mL LY333328, and 8 micrograms/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 microgram/mL LY333328, and 4 micrograms/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by < 0.125 microgram/mL LY333328, and 0.25 microgram/mL LY333328 was bactericidal against all S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent.
我们报告了LY333328对35株耐万古霉素肠球菌临床分离株（包括经PCR检测携带vanA、vanB、vanC - 1和vanC - 2/3基因的菌株）、33株耐甲氧西林金黄色葡萄球菌临床分离株以及29株高水平耐青霉素肺炎链球菌临床分离株的活性。所有耐万古霉素肠球菌分离株均被2微克/毫升的LY333328抑制，8微克/毫升的LY333328对所有测试分离株具有杀菌作用。所有耐甲氧西林金黄色葡萄球菌分离株均被1微克/毫升的LY333328抑制，4微克/毫升的LY333328对所有测试的耐甲氧西林金黄色葡萄球菌分离株具有杀菌作用。所有耐青霉素肺炎链球菌分离株均被<0.125微克/毫升的LY333328抑制，0.25微克/毫升的LY333328对所有测试的肺炎链球菌分离株具有杀菌作用。LY333328是一种有前景的新型糖肽类抗菌剂。
Zotero 插件